New Drug for Hemophilia A Approved by FDA

By Nikki Kean

The FDA has approved a new prophylactic treatment for adults and adolescents 12 years of age and older with hemophilia A. Jivi (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) has an extended half-life that allows for twice-weekly initial dosing and then every five days (or longer) based on bleeding episodes, according to a press release from Bayer, the drug’s manufacturer.